Quarter ended Sept 2026: consolidated revenue up 23%, profit after tax down 31% vs Sept 2025
PLATIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated quarter ended 30 September 2026: revenue rose 23.3% to Rs 1,212.66 million from Rs 983.78 million in the year-ago quarter, while profit after tax fell 30.8% to Rs 75.98 million from Rs 109.83 million. Operating margin before interest, tax, depreciation and amortisation narrowed from 13.8% to 8.9%. The auditor qualified both reviews over an unconfirmed Rs 98.19 million insurance claim.
Revenue growth helps, but profit and margins weakened, which may pressure the stock. The qualified review adds uncertainty over the insurance claim.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹121.3 Cr | ₹98.38 Cr | +23.3% |
| Operating profit | ₹7.74 Cr | ₹11.21 Cr | −30.9% |
| Profit after tax | ₹7.60 Cr | ₹10.98 Cr | −30.8% |
| EBITDA margin | 8.9% | 13.3% | −4.3 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.